Leerink Partners raised the price target for the Q32 Bio Inc. (NASDAQ:QTTB) stock to “an Outperform”. The rating was released on May 21, 2024, according to finviz. The research report from Piper Sandler has initiated the stock to Overweight, with a price target set at $45. The stock was downgraded by Robert W. Baird, who disclosed in a research note on July 28, 2023, from Outperform to Neutral and set the price objective to $1.50. In their research brief published February 22, 2022, BTIG Research analysts reiterated the Q32 Bio Inc. stock to Neutral with a price target of $29.
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated -8.10% within the last five trades and -0.18% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 186.20% in the last 6 months and 65.16% was added to its value over the previous 3 months. QTTB stock is trading at a margin of -1.93%, 12.03% and 53.37% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Sponsored
As of the close of trading, QTTB deals in the Healthcare domain. The stock is trading -16.82 percent below its 52-week high and 231.76 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 94. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Q32 Bio Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at -7967.30 percent and the profit margin is -9771.71 percent, and the company has reported a gross margin of -11.33 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $326.56 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 281.52 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 1.21, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 67.86 percent of Q32 Bio Inc. shares are owned by insiders, and 8.46 percent are held by financial institutions. Alloway Paul, the at Q32 Bio Inc. (QTTB) has sold 268 shares of firm on Mar 25 ’24 at a price of $24.21 against the total amount of $6488.0. In another inside trade, Michaud Charles Jr, of Q32 Bio Inc. (NASDAQ:QTTB) sold 75 shares of the firm on Mar 25 ’24 for a total worth of $1815.0 at a price of $24.20. An inside trade which took place on Jan 09 ’24, Director of Q32 Bio Inc. TZIANABOS ARTHUR sold 13,037 shares of firm against total price of $7445.0 at the cost of $0.57 per share.
